The Prescription of Success: Improving Pipelines, Increasing Capabilities - Research Report on Globus, Akorn, Anika, Orthofix and Sangamo Biosciences

NEW YORK, March 5, 2013 /PRNewswire/ --

Today, Investors Alliance announced new research reports highlighting Globus Medical Inc (NYSE: GMED), Akorn, Inc. (NASDAQ: AKRX), Anika Therapeutics, Inc. (NASDAQ: ANIK), Orthofix International NV (NASDAQ: OFIX) and Sangamo Biosciences, Inc. (NASDAQ: SGMO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Globus Medical Inc Research Report

Globus delivered a strong year with worldwide sales of $386 million, up 16.4 percent from 2011. The company was also able to increase its diluted EPS by 46.7 percent over the fourth quarter. Globus Chairman and CEO Dave Demski was pleased with the company's revenue growth, profitability, and strong IPO and product developments. Globus continues to invest in expanding its facilities to drive growth. It is also expanding globally, establishing its presence in 24 countries. Because of its strong growth prospects, Piper Jaffray raised their price target on Globus to $22. They currently maintain an Overweight rating. The Full Research Report on Globus Medical Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/09f5_GMED] - Bad link

--

Akorn, Inc. Research Report

Shares for Akorn rallied by more than 6.5 percent after the company reported its fourth quarter earnings. Akorn's profit climbed 54 percent, as acquisitions and newly approved products helped improve revenue. The company's adjusted earnings of 13 cents per share beat analysts' estimates by a cent. To continue its strong momentum, Akorn is planning to further invest in R&D while expanding its facilities in India to build new capacities. Akorn's R&D pipeline includes 56 abbreviated new drug applications (ANDA), with combined annual addressable IMS market size of about $5.8 billion. The company is on its way to file 10 additional products in the near future. The Full Research Report on Akorn, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/60e9_AKRX]

--

Anika Therapeutics, Inc. Research Report

Anika Therapeutics gave investors a reason to celebrate after reporting fourth quarter revenue that increased 23 percent and earnings that jumped 48 percent. The strong growth was attributed to the strong sales for orthovisc, the company's flagship orthiobiologics product. Orthovisc closed the year as the market leading product. The company is also taking steps for the regulatory approval of Monovisc. The company intends to improve its manufacturing capabilities in order to meet the high level of demand for its products. Its promising pipeline is also another reason to be excited. The Full Research Report on Anika Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/25da_ANIK]

--

Orthofix International NV Research Report

Orthofix CEO Robert Vaters purchased 3000 shares at a price of $35.97, showing his confidence in his company's prospects. Following his purchase, shares for Orthofix moved up by almost 3 percent. Vaters has expressed his desire to overcome near-term challenges and improve the company's margins. A better financial standing would allow the company to further develop its pipeline and drive growth. In the coming year, the company expects constant currency net sales growth from 1 to 3 percent over 2012. The Full Research Report on Orthofix International NV - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/a593_OFIX]

--

Sangamo Biosciences, Inc. Research Report

Shares for Sangamo Biosciences rose by 9.45 percent after a Lazard Capital Markets analyst started coverage on the company with a Buy rating and a price target of $16 per share. The analyst noted that the company's products could be "a big step forward for gene therapy." He also commended the company's effort to study drugs that have limited treatment options. The company is expecting to report data from mid-stage clinical trials for HIV and AIDS within the year. Earlier this month, the company reported fourth quarter revenue of $8.9 million compared to $4.7 million in the fourth quarter of 2011. The Full Research Report on Sangamo Biosciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.Investors-Alliance.com/r/full_research_report/4ad5_SGMO]

--

Consider Investors Alliance

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Patricia Byers
Email: [email protected]
Main: +1-480-745-7826

SOURCE Investors-Alliance